Stifel Reiterates Buy on Krystal Biotech, Raises Price Target to $204
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has reiterated a Buy rating on Krystal Biotech (NASDAQ:KRYS) and increased the price target from $178 to $204.

April 16, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha reiterates a Buy rating on Krystal Biotech and raises the price target from $178 to $204.
The reiteration of a Buy rating combined with an increased price target by a reputable analyst like Dae Gon Ha suggests a strong bullish sentiment towards Krystal Biotech. This is likely to positively influence investor perception and could lead to a short-term increase in the stock price as market participants adjust their valuations based on the new price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100